Home/Filings/4/0001415889-25-012287
4//SEC Filing

Roemer Alan S. 4

Accession 0001415889-25-012287

CIK 0001740279other

Filed

May 6, 8:00 PM ET

Accepted

May 7, 8:45 PM ET

Size

23.4 KB

Accession

0001415889-25-012287

Insider Transaction Report

Form 4
Period: 2025-04-27
Transactions
  • Award

    Series B Warrants (right to buy)

    2025-04-27+91,45991,459 total
    Exercise: $0.45Exp: 2028-12-13Common Stock (91,459 underlying)
  • Exercise/Conversion

    Common Stock

    2025-04-30$0.18/sh+11,000$2,028398,489 total
  • Award

    Series B Warrants (right to buy)

    2025-04-27+11,00011,000 total
    Exercise: $0.18Exp: 2025-05-02Common Stock (11,000 underlying)
  • Disposition to Issuer

    Series A Warrants (right to buy)

    2025-04-27102,4590 total
    Exercise: $0.45Exp: 2025-10-04Common Stock (102,459 underlying)
  • Exercise/Conversion

    Series A Warrants (right to buy)

    2025-04-30102,4590 total
    Exercise: $0.18Exp: 2025-05-02Common Stock (102,459 underlying)
  • Disposition to Issuer

    Series B Warrants (right to buy)

    2025-04-27102,4590 total
    Exercise: $1.50Exp: 2028-12-13Common Stock (102,459 underlying)
  • Exercise/Conversion

    Common Stock

    2025-04-30$0.18/sh+102,459$18,893387,489 total
  • Award

    Series A Warrants (right to buy)

    2025-04-27+102,459102,459 total
    Exercise: $0.18Exp: 2025-05-02Common Stock (102,459 underlying)
  • Exercise/Conversion

    Series B Warrants (right to buy)

    2025-04-3011,0000 total
    Exercise: $0.18Exp: 2025-05-02Common Stock (11,000 underlying)
Footnotes (5)
  • [F1]The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.
  • [F2]Fully vested and exercisable.
  • [F3]The reported securities are included within 102,459 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock.
  • [F4]The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date.
  • [F5]The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.

Issuer

IN8BIO, INC.

CIK 0001740279

Entity typeother

Related Parties

1
  • filerCIK 0001643070

Filing Metadata

Form type
4
Filed
May 6, 8:00 PM ET
Accepted
May 7, 8:45 PM ET
Size
23.4 KB